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Blocking IL-1 in systemic inﬂammation
 
Charles A. Dinarello
 
A growing number of systemic inflammatory diseases characterized in part by 
recurrent fevers, leukocytosis, anemia, and elevated acute phase proteins are 
linked to interleukin (IL)-1 activity since rapid and sustained resolution is 
observed upon specific blockade of IL-1 receptors. Rapid resolution of systemic 
and local inflammation is now also reported in systemic onset juvenile idiopathic 
arthritis (SoJIA). Loss of control of the secretion of IL-1
 
 
 
 might be a common 
mechanism explaining the aberrant activity of IL-1 in these diseases.
 
IL-1 synthesis and regulation
 
The production of IL-1
 
 
 
 is via non-
classical pathways of protein secretion.
Toll-like receptor (TLR) agonists such
as endotoxins initiate the synthesis of
the inactive IL-1
 
 
 
 precursor (Fig. 1 A).
Although most of the IL-1
 
 
 
 precursor
is in the cytosol, a fraction moves
into specialized secretory lysosomes (1).
There the IL-1
 
 
 
 precursor colocalizes
with procaspase-1 (1) (Fig. 1 B). The
next step is the conversion of the inac-
tive procaspase-1 to active caspase-1 by
a complex of proteins termed the “IL-1
 
 
 
inflammasome” (2). Current thinking
is that in resting cells procaspase-1 is
bound to a large inhibitor molecule,
which prevents its activation. During
initiation of IL-1
 
 
 
 synthesis, there is
activation of caspase-1, which then
processes the IL-1
 
 
 
 precursor into a
mature form ready for secretion. Pro-
cessing and release are closely linked
(Fig. 1, C and D). Activation of the
nucleotide P2X7 receptor triggers the
efflux of potassium ions out of the cell ,
and within minutes the secretory lyso-
somes begin releasing their contents of
processed IL-1
 
 
 
 into the extracellular
milieu. In support of the role of P2X7,
overexpression of the receptor increases
the secretion of IL-1
 
 
 
 (3) and its absence
prevents the secretion of IL-1
 
 
 
 (4).
The small peptide LL37 released from
activated neutrophils and epithelial cells
also stimulates the release of processed
IL-1
 
 
 
 via the P2X7 receptor (5). The
efflux of potassium ions signals the in-
flux of calcium ions (3), which in turn
activate phospholipases (6). It appears
that calcium-independent phospholipase
A2 is required for caspase-1 processing in
the specialized lysosomes, whereas phos-
phatidylcholine-specific phospholipase C
is required for lysosomal exocytosis and
release (6). Dysregulation in any of these
steps might account for increased secre-
tion of IL-1
 
 
 
 and for IL-1–mediated
diseases.
 
IL-1 dysregulation in SoJIA
 
SoJIA (also known as systemic juvenile
rheumatoid arthritis) is a devastating,
systemic inflammatory disease that affects
growing children for which there are
few treatment options other than high
dose corticosteroid treatment. In this
issue, Pascual and colleagues show that
blocking IL-1 activity with an IL-1 re-
ceptor antagonist (IL-1Ra, anakinra)
resulted in convincing clinical and hema-
tological responses in nine patients with
SoJIA (7). Resolution of clinical symp-
toms including fever, marked leukocyto-
sis, thrombocytosis, elevated erythrocyte
sedimentation, anemia, and arthritis
were rapid and sustained. The efficacy
of IL-1Ra in these children contrasts
sharply to that of blocking TNF in
SoJIA. Neutralization of TNF, a success-
ful  treatment in some patients with
rheumatoid arthritis, is now discredited
in SoJIA since the TNF inhibitors etaner-
cept and infliximab are associated with
treatment failures, worsening of disease
and/or exacerbations of other autoim-
mune diseases in these patients. Based
on the present study and a similar ob-
servation (8), blocking IL-1 may become
the standard of therapy for SoJIA. At
present, only IL-1Ra is approved for
use in humans, but other agents such as
anti–IL-1
 
 
 
 monoclonal antibodies or
the IL-1 Trap molecule (9) reduce IL-1
activity and are likely to be effective.
The rapid resolution of clinical, hemato-
logical, and biochemical manifestations of
SoJIA after a few days of IL-1Ra treat-
ment is reminiscent of the treatment of
refractory adult onset Still’s disease, a
systemic inflammatory disease of adults
characterized by similar manifestations
of disease seen in SoJIA. (10). In SoJIA
patients, reduction or complete with-
drawal of long-term steroid treatment
was achieved without a rebound in dis-
ease activity, as is also the case in adult
onset Still’s disease patients treated with
IL-1Ra. For growing children, IL-1Ra
therapy is safe and may eliminate the
stunted growth associated with steroid
therapy. In addition, IL-1Ra therapy in
rheumatoid arthritis patients does not
interfere with tetanus immunization,
suggesting that this treatment will not
interfere with childhood immunizations.
Pascual and coworkers took their
investigation of disease mechanisms a step
further than most studies. They added
20% serum from four SoJIA patients or
from healthy controls to peripheral blood
mononuclear cells (PBMCs) of healthy
donors, and changes in gene expression
were assessed by microarray analysis (7).
Why these four sera of the 16 patients
available to the authors were selected is
not specified, nor is the reason for using
20% serum. Nevertheless, increases in
gene expression of cytokines, cytokine
receptors, cell adhesion molecules, and
other markers of inflammation were
observed in PBMCs incubated with
patient sera but not control sera. The
gene most highly induced by SoJIA sera
was fibronectin (17-fold). The authors
found that incubating PBMCs with
20% serum from SoJIA patients in-
creased secretion of IL-1
 
 
 
 compared
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with autologous sera. Furthermore, it
appeared that the sera from patients
with systemic disease induced more
IL-1
 
 
 
 secretion compared with pa-
tients with only active arthritis. It may
be concluded that 20% serum from
patients with SoJIA contains enough
stimulant(s) to increase a portfolio of
proinflammatory genes as well as in-
duce secretion of IL-1
 
 
 
 from healthy
PBMCs, and that autologous sera does
not contain such stimulants. In my
opinion, however, such methods do
not support the concept that disease is
caused by a circulating factor(s); rather,
the effects of sera on cultured cells
may be an epiphenomenon. Presence
of TLR ligands, such as bacterial li-
popolysaccharide, in SoJIA sera would
yield the same results, and a combina-
tion of particular serum acute phase
reactants could also contribute to the
observation. If the authors had added
IL-1Ra to the cultures, they could have
at least observed whether the serum
stimulant(s) was IL-1 itself.
The authors also examined steady-
state gene expression in PBMCs from
16 SoJIA patients with active disease
and compared the results to PBMCs
from 12 healthy children. Many of the
same genes induced by SoJIA sera were
spontaneously increased in the PBMCs
of these 16 patients. Most notable and
significant were the genes encoding IL-
1
 
 
 
, the IL-1 decoy receptor, cyclo-
oxygenase-2, TLR-2, and the comple-
ment receptor C1q. Pentraxin-3, an
IL-1
 
 
 
–inducible gene (11), was also
highly overexpressed, and being an
acute phase protein, it likely contrib-
utes to the high sedimentation rate of
red blook cells in SoJIA. Some genes
that were up-regulated by the SoJIA
sera were not increased in steady-state
mRNA from PBMCs of the 16 pa-
tients, including several chemokines
and fibronectin, casting doubt on the
relevance of the high expression level
these genes have in serum studies. An-
other potentially relevant gene overex-
pressed in SoJIA PBMCs is a potassium
channel gene 
 
KCNJ15
 
. As discussed
above, influx of potassium ions is a
trigger for activation of caspase-1 and
secretion of IL-1
 
 
 
 in response to
activation of the nucleotide recep-
tor P2X7.
Measurement of circulating IL-1
 
 
 
is not a reliable indicator of a role for
this cytokine in disease, nor does it pro-
vide rationale for selection of a thera-
peutic intervention such as IL-1Ra.
IL-1
 
 
 
 is a highly active cytokine in hu-
mans; injecting a few nanograms per
kilogram results in fever, neutrophilia,
thrombocytosis, acute phase proteins,
and circulating IL-6 (for review see ref-
erence 12). Thus, circulating levels of
IL-1
 
 
 
 in the picomolar range may eas-
ily escape detection by routine ELISAs
or similar methods. Although there are
numerous reports that circulating cy-
tokine levels correlate with severity in a
variety of diseases, it is only specific
blockade or neutralization of a cytokine
that provides a convincing case for cau-
sation. For this reason, the study by
Pascual et al. is compelling (7). It is a
general concept that IL-1–mediated dis-
ease severity is regulated at the level
of ligand production and activity, and
not at the receptor level. For example,
IL-1 type I receptors are expressed on
all cells in healthy individuals and in-
creases of only two- or threefold occur
in disease. On the other hand, in circu-
lating monocytes and bone marrow
macrophages from healthy individuals,
IL-1
 
 
 
 gene expression is absent but in-
creases at least 100-fold when stimulated
Figure 1. Steps in the processing and secretion of IL-1 . (A) TLR ligands such as endotoxin 
trigger gene expression and synthesis of the IL-1  precursor, which remains diffusely in the cytosol. 
In the same cell, inactive procaspase-1 is bound to components of the IL-1  inflammasome, which 
contains the products of the NALP-3 gene. The IL-1  inflammasome is kept in an inactive state by 
binding to a large molecular weight putative inhibitor. (B) After TLR signals, there is a transient 
uncoupling of the inhibitor and NALP-3 gene products from procaspase-1, which then colocalizes 
with the IL-1  in secretory lysosomes. (C) Activation of the nucleotide receptor P2X7 by ATP or LL37 
initiates the efflux of potassium from the cell via a potassium channel. The efflux of potassium 
activates the autocatalytic processing of procaspase-1. Active caspase-1 cleaves the IL-1  precursor 
in an active cytokine. (D) The efflux of potassium ions results in the influx of calcium ions, which in 
turn activate phospholipases. Phosphatidylcholine-specific phospholipase C (PC-PLA-2) facilitates 
lysosomal exocytosis and secretion of IL-1.
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with microbial products or inflamma-
tory molecules, including products of
activated T cells. The total amount of
IL-1
 
 
 
 precursor that is synthesized,
however, does not necessarily equate to
the amount of active IL-1
 
 
 
 that is pro-
duced, as the caspase-1–dependent con-
version of IL-1
 
 
 
 precursor to an active
secreted cytokine is a tightly controlled
event, despite the presence of constitu-
tive procaspase-1 in the same cell. Hence,
the increase in IL-1
 
 
 
 secretion from
PBMCs of SoJIA patients is a highly
relevant observation.
The study by Pascual and cowork-
ers provides evidence for increased se-
cretion of IL-1
 
 
 
 by freshly cultured
PBMCs from these patients compared
with PBMCs from healthy subjects (7).
In the absence of exogenous stimula-
tion, cultured PBMCs from healthy
subjects do not release IL-1
 
 
 
, but upon
stimulation synthesize the IL-1
 
 
 
 pre-
cursor and release the processed form of
IL-1
 
 
 
 into the supernatant. However,
more than 50% of the total IL-1
 
 
 
precursor synthesized remains inside
monocytes from healthy donors. The
amount of IL-1
 
 
 
 released from PBMCs
of five SoJIA patients was more than
10-fold greater than five healthy con-
trols (7). In the same cultures, the re-
lease of TNF and IL-6 was similar for
healthy and affected subjects, suggesting
that the elevated release of IL-1
 
 
 
 was
not due to increased monocyte num-
bers or increased activation of SoJIA
PBMCs. Unfortunately, IL-1
 
 
 
 secre-
tion was induced using the unorthodox
combination of PMA plus ionomycin,
whereas most studies of dysfunctional
IL-1
 
 
 
 release use TLR agonists. Never-
theless, the disease-related increase in
IL-1
 
 
 
 secretion may explain the role
for IL-1 and the responses to IL-1Ra in
these patients who failed to respond to
conventional treatments.
 
Secretion of IL-1
 
 
 
 in other inflammatory 
diseases: a unifying mechanism?
 
Increased secretion of IL-1
 
 
 
 from cul-
tured PBMCs has also been reported
for a growing number of inherited,
chronic autoinflammatory syndromes,
each of which responds to IL-1Ra (13–
16). In these syndromes, increased se-
cretion of IL-1
 
 
 
 is due to a single
amino acid mutation in the 
 
NALP-3
 
gene, which controls the activation of
caspase-1 found in the IL-1
 
 
 
 inflam-
masome (17). Similar to the situation in
SoJIA, circulating levels of IL-1
 
 
 
 are
not detected in these patients (13) but
increased secretion of IL-1
 
 
 
 is ob-
served in vitro. The single point muta-
tion in the 
 
NALP-3
 
 gene causes the
loss of tight control of IL-1
 
 
 
 process-
ing. As a result, relatively minor stresses
such as exposure to cold results in in-
creased secretion of IL-1
 
 
 
 with conse-
quent systemic disease (13). It appears
that the 
 
NALP-3
 
 gene provides an
important roadblock to control the
secretion of IL-1
 
 
 
 and raises the issue
of a defective roadblock in SoJIA. Al-
though the reason for the increased se-
cretion of IL-1
 
 
 
 in the SoJIA patients
remains unclear, both SoJIA patients
and patients with 
 
NALP-3
 
 mutations
share the phenotype of systemic disease
and increased secretion of processed
IL-1
 
 
 
 in vitro. There are chronic in-
flammatory syndromes without muta-
tions in the 
 
NALP-3
 
 gene but never-
theless elevated IL-1
 
 
 
 release in vitro
and also respond to IL-1Ra therapy;
presently, these are mutation-negative
neonatal onset multisystem inflamma-
tory disease (NOMID; reference 18),
pyogenic arthritis, pyoderma gangreno-
sum, acne syndrome (PAPA; reference
19), and familial Mediterranean fever
(FMF; reference 20). Both PAPA and
FMF are genetic diseases associated
with the intracellular protein pyrin,
Figure 2. Systemic manifestations of IL-1 . Active IL-1  is secreted by many cell types including 
monocytes and macrophages (center). IL-1  enters the circulation and triggers IL-1 receptors on the 
hypothalamic vascular network resulting in synthesis of cyclooxygenase-2, which causes brain levels 
of prostaglandin E2 to rise, thus activating the thermoregulatory center for fever production (refer-
ence 27). In the periphery, IL-1  activates IL-1 receptors on the endothelium resulting in rashes and 
the production of IL-6. Circulating IL-6 stimulates liver hepatocytes to synthesize several acute phase 
proteins, which accounts for the increase in erythrocyte sedimentation rate in SoJIA. IL-1 also acts on 
the bone marrow to increase mobilization of granulocyte progenitors and mature neutrophils, result-
ing in peripheral neutrophilia. IL-1–induced IL-6 increases platelet production, which results in throm-
bocytosis. IL-1 also causes decreased response to erythropoietin, which causes anemia.
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which participates in maintaining pro-
caspase-1 as an inactive enzyme. Muta-
tions of the 
 
Pyrin
 
 gene in mice, similar
to those found in humans with FMF,
result in increased caspase-1 activity
and increased secretion of IL-1
 
 
 
 (21).
Although these systemic, multisys-
tem syndromes are not common dis-
eases, they reveal a fundamental role
for IL-1 in systemic inflammation re-
gardless of the cause. As shown in Fig.
2, IL-1 affects several targets that ac-
count for the manifestations of systemic
disease. These are recurrent fevers,
neutrophilia, thrombocytosis, elevated
serum amyloid A and C–reactive pro-
tein, and anemia. Skin rashes and urti-
caria are also common. Hearing loss,
developmental delay, and aseptic men-
ingitis can also be observed in child-
hood. The endothelium is a prime tar-
get for IL-1–mediated inflammation as
IL-1 receptors on the endothelium
trigger prostaglandin E production,
cause bone marrow release of neutro-
phils, and induce the production of
IL-6. In fact, IL-1 induction of IL-6 ac-
counts for hepatic acute phase protein
synthesis and the thrombocytosis. The
finetuning of IL-1–mediated inflamma-
tion is revealed upon stopping and
restarting IL-1Ra. Upon cessation of
IL-1Ra therapy, clinical signs and symp-
toms of disease as well as biochemical
and hematological abnormalities re-
bound within days and resolve upon
resumption of IL-1 receptor blockade
(10, 14–16). In the Pascual study, IL-
1Ra therapy was temporarily with-
drawn in two patients due to viral-like
illness, during which time the erythro-
cyte sedimentation rate increased, only
to fall upon restarting therapy (7).
Although SoJIA clearly fits with the
clinical, hematological, and biochemical
manifestations of the autosomal domi-
nant autoinflammatory syndromes, and
although SoJIA shares with these inher-
ited diseases increased secretion of IL-
1
 
 
 
, no genetic mutations have yet been
described in SoJIA patients that relate to
IL-1
 
 
 
 secretion or any other genetic
marker. However, to our knowledge
no systematic examination of gene de-
fects in the components of the IL-1
 
 
 
inflammasome has been made in SoJIA.
There is no clear pattern of inheritance
in SoJIA, and like other autoimmune
diseases, the incidence is greater in fam-
ilies but without identification of a spe-
cific gene or mutation.
It is likely that other agents that pre-
vent IL-1
 
 
 
–mediated disease will be ef-
fective in SoJIA. These are the IL-1
Trap, IL-1
 
 
 
–specific monoclonal anti-
bodies, IL-1 receptor type I–specific
monoclonal antibodies, and the caspase-1
inhibitor (22). It is also possible that
agents that inhibit the nucleotide recep-
tor P2X7 will reduce IL-1
 
 
 
–mediated
disease (23). If SoJIA is due to dysfunc-
tional control of caspase-1 activity or
the P2X7 receptor, treatment options
may be targeted to the mechanism of
IL-1
 
 
 
 secretion. It is a general principal
in therapeutics to target the most distal
mechanism of a disease process. Several
levels of control of the synthesis, pro-
cessing, and secretion of IL-1
 
 
 
 have
evolved, and one may assume that these
function to limit inflammation. More-
over, once released, IL-1
 
 
 
 must con-
tend with competition for receptor oc-
cupancy with the naturally occurring
IL-1Ra, the binding and neutralization
by the IL-1 type II decoy receptor (24),
and the formation of inactive com-
plexes with constitutively secreted solu-
ble IL-1 receptor accessory protein (25,
26), each of which also limit IL-1
 
 
 
 re-
sponses. Although increased secretion
of IL-1
 
 
 
 may account for IL-1 activity
in SoJIA, loss of control of these addi-
tional mechanisms may also be dis-
rupted in SoJIA.
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